Medicine
Methotrexate 250 mg/10 mL injection
Methotrexate 250 mg/10 mL injection is a generic prescription medicine for intra-arterial, intramuscular, intravenous use, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20° to 25°C (68° to 77°F). PROTECT FROM LIGHT.
Key facts
- Active ingredient (INN)
- Methotrexate
- Brand
- Sold under the generic name
- Strength
- 250 mg/10 mL
- Dosage form
- Injection
- Route
- Intra-arterial, intramuscular, intravenous
- Packs
- 1 vial of 10 mL
- Manufacturer
- Fresenius Kabi
- Origin register
- US FDA, United States
- Storage
- Store at 20° to 25°C (68° to 77°F). PROTECT FROM LIGHT.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L01BA01 Methotrexate
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 10 September 2001
- Identifiers
- RxCUI 1946772DailyMed set ID b585f621-f6c9-4735-ab61-bd1b401f3df0NDC 63323-123Application ANDA040263
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
Packs from every labeler of this generic presentation.
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial in 1 carton / 10 mL in 1 vial | 63323-123-10 | Fresenius Kabi | 10 September 2001 |
| 1 vial in 1 carton / 10 mL in 1 vial | 16729-277-03 | — | 7 March 2014 |
| 1 vial in 1 box / 10 mL in 1 vial | 0143-9516-01 | — | 5 January 2018 |
| 1 vial, single-dose in 1 carton / 10 mL in 1 vial, single-dose | 0703-3675-01 | — | 1 August 2012 |
| 1 vial in 1 carton / 10 mL in 1 vial | 55150-513-01 | — | 11 September 2024 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Methotrexate 250 mg/10 mL injection.
Other strengths and forms of Methotrexate
Clinical summary
Methotrexate is a folate analog metabolic inhibitor indicated for neoplastic diseases for the, among other approved uses. It is available as injection, tablets and powder for injection for oral, subcutaneous and intramuscular use. MedsAcross supplies Methotrexate for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about MethotrexateFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Methotrexate prescribing information (Hospira) · U.S. National Library of Medicine, DailyMed
- Jylamvo: European public assessment report (EPAR) · European Medicines Agency
- Nordimet: European public assessment report (EPAR) · European Medicines Agency
Need Methotrexate 250 mg/10 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.